作者
Michael Fuchs, Helen Goergen, Carsten Kobe, Georg Kuhnert, Andreas Lohri, Richard Greil, Stephanie Sasse, Max S Topp, Erhardt Schaefer, Bernd Hertenstein, Martin Soekler, Martin Vogelhuber, Josee M Zijlstra, Ulrich Bernd Keller, Stefan W Krause, Martin Wilhelm, Georg Maschmeyer, Julia Thiemer, Ulrich Duehrsen, Julia Meissner, Andreas Viardot, Hans Eich, Christian Baues, Volker Diehl, Andreas Rosenwald, Bastian Von Tresckow, Markus Dietlein, Peter Borchmann, Andreas Engert
发表日期
2019/11/1
期刊
Journal of clinical oncology
卷号
37
期号
31
页码范围
2835-2845
出版商
American Society of Clinical Oncology
简介
PURPOSE
Combined-modality treatment (CMT) with 2× ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and small-field radiotherapy is standard of care for patients with early-stage favorable Hodgkin lymphoma (HL). However, the role of radiotherapy has been challenged. Positron emission tomography (PET) after 2× ABVD (PET-2) might help to predict individual outcomes and guide treatment.
METHODS
Between November 2009 and December 2015, we recruited patients age 18 to 75 years with newly diagnosed, early-stage favorable HL for this international randomized phase III trial. Patients were assigned to standard CMT of 2× ABVD and 20-Gy involved-field radiotherapy or PET-guided treatment, omitting involved-field radiotherapy after negative PET-2 (Deauville score < 3). Primary objectives were to exclude inferiority of 10% or more in 5-year progression-free survival (PFS) of ABVD alone …
学术搜索中的文章
M Fuchs, H Goergen, C Kobe, G Kuhnert, A Lohri… - Journal of clinical oncology, 2019